Cabergoline for levodopa-induced complications in Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2001, Issue 1, 2001, Pages

  Clarke, Carl E ^a   Deane, Katherine H O ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; LEVODOPA; PLACEBO; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADJUVANT THERAPY; CLINICAL EFFECTIVENESS; CONFUSION; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; HALLUCINATION; HUMAN; INSOMNIA; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; ERGOLINES; HUMANS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS;

EID: 0035220893     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001518     Document Type: Review

References (9)

1. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clinical Neuropharmacology 1996;19:202-212.
2. Hutton JT, Koller WC, Ahlskog JE, et al. Multicentre, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-1065.
3. Miguel F, Obeso JA, Olive Plana JM, Tolosa E, Villaueva Eusa JA, Dubini A, et al. Double-blind parallel group study of the efficacy and tolerability of the cabergoline vs placebo in Parkinsonian patients with motor fluctuations. FCE Report: 21336/722i, Clinical Reference 29 1993.
4. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonains with motor fluctuations. Journal of Neurology 1996;243:68-72.
5. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Archives of Neurology 1994;51:1236-1241.
6. Ahlskog EJ, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clinical Neuropharmacology 1996;19:202-212.
7. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. Journal of the American Medical Association 1996;276(8):637-639.
8. Quinn N, Critchley P, Parkes D, Marsden CD. When should levodopa be started?. Lancet 1986;ii:985-986.
9. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease. Neurology 1984;34:991-996.